Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Opthea Terminates Phase 3 Wet AMD Trials After ShORe Fails To Meet Primary Endpoint, Citing Lack Of Visual Benefit

Author: Benzinga Newsdesk | March 31, 2025 02:27am
  • ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
  • Opthea and DFA Investors agreed to terminate both COAST and ShORe trials
  • Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern

Posted In: OPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist